Literature DB >> 28782656

Genetics and mechanisms of hepatic cystogenesis.

L F M van de Laarschot1, J P H Drenth2.   

Abstract

Polycystic liver disease (PLD) is a heterogeneous genetic condition. PKD1 and PKD2 germline mutations are found in patients with autosomal dominant polycystic kidney disease (ADPKD). Autosomal dominant polycystic liver disease (ADPLD) is associated with germline mutations in PRKCSH, SEC63, LRP5, and recently ALG8 and SEC61. GANAB mutations are found in both patient groups. Loss of heterozygosity of PLD-genes in cyst epithelium contributes to the development of hepatic cysts. A genetic interaction network is implied in hepatic cystogenesis that connects the endoplasmic glycoprotein control mechanisms and polycystin expression and localization. Wnt signalling could be the major downstream signalling pathway that results in hepatic cyst growth. PLD in ADPLD and ADPKD probably results from changes in one common final pathway that initiates cyst growth. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Liver cysts; Polycystic liver disease

Mesh:

Substances:

Year:  2017        PMID: 28782656     DOI: 10.1016/j.bbadis.2017.08.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  8 in total

Review 1.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 2.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

Review 3.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

Review 4.  Molecular Mechanisms of Isolated Polycystic Liver Diseases.

Authors:  Ziqi Yu; Xiang Shen; Chong Hu; Jun Zeng; Aiyao Wang; Jianyong Chen
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

Review 5.  Polycystic Liver Disease: Advances in Understanding and Treatment.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Annu Rev Pathol       Date:  2021-11-01       Impact factor: 23.472

6.  Estrogen-Containing Oral Contraceptives Are Associated With Polycystic Liver Disease Severity in Premenopausal Patients.

Authors:  René M M van Aerts; Lucas H P Bernts; Tom J G Gevers; Wietske Kievit; Lisanne Koopmans; Theodoor E Nieboer; Frederik Nevens; Joost P H Drenth
Journal:  Clin Pharmacol Ther       Date:  2019-07-23       Impact factor: 6.875

7.  JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging.

Authors:  Katrin Müller; Hanna Honcharova-Biletska; Christiane Koppe; Michèle Egger; Lap Kwan Chan; Anne T Schneider; Lena Küsgens; Friederike Böhm; Yannick Boege; Marc E Healy; Johannes Schmitt; Sarah Comtesse; Mirco Castoldi; Christian Preisinger; Marta Szydlowska; Enrico Focaccia; Nadine T Gaisa; Sven H Loosen; Simone Jörs; Frank Tacke; Christoph Roderburg; Verena Keitel; Johannes G Bode; Peter Boor; Roger J Davis; Thomas Longerich; Fabian Geisler; Mathias Heikenwalder; Achim Weber; Mihael Vucur; Tom Luedde
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 11.205

8.  Liver Involvement in Congenital Disorders of Glycosylation: A Systematic Review.

Authors:  Rossella Colantuono; Elisa D'Acunto; Daniela Melis; Pietro Vajro; Hudson H Freeze; Claudia Mandato
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-10-01       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.